225Ac标记的小胃泌素类似物DOTA-CCK-66用于靶向α治疗的临床前评估
在AR42J荷瘤394-NOD SCID小鼠中比较[177Lu]Lu-DOTA-CCK-66与[225Ac]Ac-DOTA-CCK-66的单次治疗,对照组注射[68Ga]Ga-DOTA-CCK-66(1.1 MBq)行PET/CT显像。治疗组肿瘤体积先降后生长显著延迟,177Lu组和225Ac组平均生存期分别较未治疗组延长3倍(37±3天)和4.5倍(54±6天),血样分析未提示肝、肾或胃毒性。
要点
- 225Ac组平均生存54±6天,177Lu组37±3天,未治疗组12±3天。
- 两种治疗均观察到肿瘤体积初始下降及后续生长显著延迟。
- 血样分析未提示177Lu和225Ac治疗对肝、肾或胃的毒性副作用。
核心结论
- 研究证明177Lu和225Ac标记的DOTA-CCK-66均具有显著治疗疗效,225Ac标记物平均生存率最高,提示其用于甲状腺髓样癌患者管理中的靶向α治疗具有较高治疗潜力。
研究设计与样本
- 治疗研究分3组、每组n=5,使用AR42J荷瘤394-NOD SCID小鼠。
- 对照组注射[68Ga]Ga-DOTA-CCK-66(1.1 MBq)行PET/CT显像,治疗组单次给予[177Lu]Lu-DOTA-CCK-66(37 MBq,放射性配体治疗)或[225Ac]Ac-DOTA-CCK-66(37 kBq,靶向α治疗)。
- 每周两次监测所有动物肿瘤体积和体重至达终点标准,处死后用VetScan VS2(Abaxis)评估血样。
主要发现
- 治疗后观察到肿瘤体积初始下降,随后治疗队列肿瘤生长显著延迟。
- 177Lu治疗组平均生存37±3天,较未治疗组12±3天延长3倍。
- 225Ac治疗组平均生存54±6天,较未治疗组12±3天延长4.5倍。
- 血样分析未提示177Lu和225Ac治疗对肝、肾或胃的毒性副作用。
关键数值与推荐
- 对照组[68Ga]Ga-DOTA-CCK-66剂量1.1 MBq;[177Lu]Lu-DOTA-CCK-66单次37 MBq;[225Ac]Ac-DOTA-CCK-66单次37 kBq。
- 未治疗动物平均生存12±3天,177Lu组37±3天,225Ac组54±6天。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The recently developed metabolically more stable minigastrin derivative, DOTA-CCK-66, displayed promising preclinical data when labeled either with 68Ga or 177Lu. First positron emission tomography/computed tomography (PET/CT) imaging using [68Ga]Ga-DOTA-CCK-66 in two patients suffering from medullary thyroid carcinoma (MTC) displayed a favorable biodistribution profile. Here, we aim to investigate the therapeutic potential of [225Ac]Ac-DOTA-CCK-66 as a targeted α-therapy (TAT) agent in a comparative treatment study of [177Lu]Lu- versus [225Ac]Ac-DOTA-CCK-66. METHODS: Treatment studies were performed (3 groups, n = 5, AR42J tumor-bearing 394-NOD SCID mice). Control group animals were injected with [68Ga]Ga-DOTA-CCK-66 (1.1 MBq, PET/CT imaging), while treatment group animals received a single dose of either [177Lu]Lu-DOTA-CCK-66 (37 MBq, radioligand therapy (RLT)) or [225Ac]Ac-DOTA-CCK-66 (37 kBq, TAT). All animals' tumor volume and body weight were monitored twice a week until end-point criteria were reached. Blood samples were evaluated (VetScan VS2, Abaxis) once mice were sacrificed. RESULTS: Upon treatment, an initial decline in tumor volume, followed by a significantly delayed tumor growth of treated cohorts, was observed. Mean survival of 177Lu- as well as 225Ac-treated animals was increased by 3- (37 ± 3 d) and 4.5-fold (54 ± 6 d), respectively, when compared to non-treated animals (12 ± 3 d). Blood sample analysis did not indicate toxic side effects to the liver, kidney, or stomach upon 177Lu and 225Ac-treatment. CONCLUSION: We demonstrated a substantial therapeutic efficacy of 177Lu- and 225Ac-labeled DOTA-CCK-66. As expected, treatment with the latter resulted in the highest mean survival rates. These results indicate a high therapeutic potential of 225Ac-labeled DOTA-CCK-66 for TAT in MTC patient management.
引用
- Holzleitner N, Vilangattil M, Swaidan A, et al. Preclinical evaluation of 225Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy. Eur J Nucl Med Mol Imaging. 2024. PMID: 39392495. doi:10.1007/s00259-024-06927-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。